Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma

Abstract

Several factors have been found to affect engraftment after autologous SCT (ASCT) in multiple myeloma (MM), including source of stem cells, number of infused CD34+ cells, prior use of myelotoxic agents and use of haematopoietic growth factors post ASCT. Recently, bisphosphonates were shown to delay haematological recovery after ASCT in mice when compared to untreated controls. 1 To the best of our knowledge, this has not been studied in the clinical setting. The aim of this study was to evaluate the impact of bisphosphonates on haematological recovery after ASCT in patients with MM. We analysed 207 myeloma patients transplanted in